320: Ignite Session 7B

Presentations:

• 1:00 PM – 1:05 PM Eastern Time

  Coronary Microvascular Dysfunction in Patients with Rheumatoid Arthritis and Diabetes Mellitus: A Cross-sectional Study with 13NH3 Myocardial PET/CT
  

  Ignite Speaker: Bas Dijkshoorn, MD, MSc – Reade
• 1:05 PM – 1:10 PM Eastern Time

  The Increased Risk of Staphylococcus Aureus Bacteremia in Rheumatoid Arthritis – What Is the Impact of Glucocorticoids, Biologic Disease-Modifying Anti-Rheumatic Drugs and Disease Activity: A Danish Nationwide Nested Case-Control Study in the DANBIO Registry
  

  Ignite Speaker: Sabine Dieperink, MD – Copenhagen University Hospital - Rigshospitalet
• 1:10 PM – 1:15 PM Eastern Time

  Idiopathic Pulmonary Fibrosis Molecular Profile Correlates with Stage of Rheumatoid Arthritis-Associated Interstitial Lung Disease
  

  Ignite Speaker: Dana Ascherman, MD – University of Pittsburgh
• 1:15 PM – 1:20 PM Eastern Time

  Effect of Upadacitinib, Adalimumab, and Placebo on Residual Pain Among Patients with Rheumatoid Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment
  

  Ignite Speaker: Louis Bessette, MD, MSc – Centre de l'Ostéoporose et de Rhumatologie de Québec
• 1:20 PM – 1:25 PM Eastern Time

  Impact of Initiating Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs on Pain Medication Use in Patients with Rheumatoid Arthritis
  

  Ignite Speaker: Mengdong He, MHS – UCLA David Geffen School of Medicine
• 1:25 PM – 1:30 PM Eastern Time

  Comparison of the Effect of Different Janus Kinase Inhibitors on Activation, Function and Property of NK Cells to Control Cancer Cell Lines Proliferation: An Ex Vivo and in Vitro Study
  

  Ignite Speaker: Loïc Meudec, MD – Université Paris-Saclay
• 1:30 PM – 1:35 PM Eastern Time

  Malignancy in the Upadacitinib Clinical Trial Programs for Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
  

  Ignite Speaker: Andrea Rubbert-Roth, MD – Cantonal Hospital St Gallen
• 1:35 PM – 1:40 PM Eastern Time

  Olokizumab Improved Patient Reported Outcomes in TNF Incomplete Responder (TNF-IR) Rheumatoid Arthritis Patients: Results from the Phase III Randomized Controlled Trial
  

  Ignite Speaker: Vibeke Strand, MD, FACP, MACR – Stanford University School of Medicine, Palo Alto CA
• 1:40 PM – 1:45 PM Eastern Time

  Accelerated Waning of Protective Immunity After SARS-CoV-2 mRNA Vaccination in Patients Treated with Biological and Targeted Synthetic Disease Modifying Antirheumatic Drugs
  

  Ignite Speaker: Elisabeth Simader, MD – Department of Rheumatology , Medical University of Vienna
• 1:45 PM – 1:50 PM Eastern Time

  Targeted Synovial Tissue RNA-Seq Coupled with Artificial Intelligence Accurately Predicts Early Rheumatoid Arthritis Patients Likely to Respond to CsDMARDs, Enriching CsDMARDs Response Rates and Enabling Early Identification of Patients Requiring Subsequent Biological Therapy
  

  Ignite Speaker: Giorgio CASABURI, PhD, MSc – Exagen Inc.